Kitty Agarwal
About Kitty Agarwal
Kitty Agarwal is a Senior Principal Scientist at Bristol Myers Squibb with extensive expertise in biologics process development and cell line characterization.
Title and Current Role at Bristol Myers Squibb
Kitty Agarwal is currently a Senior Principal Scientist at Bristol Myers Squibb. In this role, she leverages her extensive experience in biologics process development to drive innovations and improvements in the company’s therapeutic manufacturing processes.
Previous Roles at Bristol Myers Squibb and KBI Biopharma
Before her current position, Kitty Agarwal served as a Senior Scientist in Biologics Process Development at Bristol Myers Squibb from 2019 to 2021. Prior to this, she held multiple roles at KBI Biopharma in Raleigh-Durham, North Carolina. She advanced from Scientist I to Senior Scientist in Cell Line Development and Process Development, working there from 2013 to 2018.
Academic Background and Education
Kitty Agarwal holds a Ph.D. in Chemistry and Biochemistry from The Ohio State University, achieved between 2008 and 2013. She also completed a Master of Science (MS) in Chemistry at The Ohio State University from 2008 to 2011. Additionally, she earned a Master of Science (MSc) in Biochemistry from the University of Calcutta between 2005 and 2007 and a Bachelor of Science (BSc) in Chemistry from St. Xavier's College, University of Calcutta, from 2002 to 2005.
Research and Professional Experience
Kitty Agarwal was previously a NSEC Graduate Fellow at The Ohio State University from 2008 to 2013, conducting research in the Department of Chemistry and Biochemistry. She also worked as a Research Associate in the Department of Biochemistry at the University of Calcutta from 2007 to 2008.
Expertise in Biologics Process Development
Kitty Agarwal specializes in high-throughput process development for biologics. Her expertise spans both small and large-scale transient expression systems, as well as the characterization of early and late-stage mammalian cell lines. She focuses on process improvement and stable cell line development for therapeutic manufacturing.